Beta-Blocker Discontinuation in Acute Heart Failure

Figures

• 

  Central Illustration. Beta-Blocker Discontinuation in Acute Heart Failure For adults hospitalized with ADHF, discontinuation of beta-blockers might be associated with higher postdischarge mortality up to 3 months though we are very uncertain about these findings. Findings on in-hospital mortality and long-term mortality were uncertain. RCT = randomized controlled trial

• 

  Figure 1. Meta-Analyses for Mortality Random-effects meta-analyses of direct pairwise adjusted comparative estimates from observational studies comparing beta-blocker discontinuation/withdrawal with continuation in adults hospitalized with ADHF. (A) In-hospital mortality (adjusted OR). (B) Short-term (≤3 months) mortality using adjusted HRs from time-to-event analyses. (C) Short-term (≤3 months) mortality using adjusted ORs as a supportive analysis. HKSJ = Hartung-Knapp-Sidik-Jonkman.

• 

  Figure 2. Meta-Analysis for Length of Stay Random-effects meta-analysis of observational studies comparing index-hospital length of stay (days) between beta-blocker discontinuation/withdrawal and continuation in adults hospitalized with ADHF. Positive mean differences indicate longer stay with discontinuation/withdrawal. Squares indicate study-specific mean differences with 95% confidence intervals; diamonds indicate pooled effects. Abbreviation as in Figure 1.